Gemini priming attenuates inflammation in human PBMCs; Phase 1b data expected mid-2025

REVELATION BIOSCIENCES, INC.

Gemini significantly decreased proinflammatory cytokines and increased anti-inflammatory cytokines vs. placebo in PBMCs challenged with HMGB-1 and LPS.
Revelation anticipates demonstrating same protective effect in cells from CKD patients in ongoing Phase 1b PRIME study.
Top-line safety, tolerability, and cellular protection data from Phase 1b expected by mid-2025.
Results support future development of GEM-CKD, GEM-AKI, and GEM-PSI programs.
CEO James Rolke called results 'game-changing' for Gemini's potential in target indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.